The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Lipoprotein(a) Levels and Risk of Coronary Heart Disease in Men: The Lipid Research Clinics Coronary Primary Prevention Trial
Abstract
OBJECTIVE: To examine the relationship between elevated levels of lipoprotein(a) [Lp(a)] and coronary heart disease (CHD) risk in a prospective study. DESIGN: Nested case-control study. The cohort consisted of participants in the Lipid Research Clinics Coronary Primary Prevention Trial. SETTING: Lipid research clinics. PARTICIPANTS: The Lipid Research Clinics Coronary Primary Prevention Trial participants (n = 3806) were men, aged 35 to 59 years, with plasma cholesterol levels of 6.85 mmol/L (265 mg/dL) or greater, low-density lipoprotein cholesterol levels of 4.91 mmol/L (190 mg/dL) or greater, and triglyceride levels less than 3.39 mmol/L. Subjects were randomly assigned to either cholestyramine or placebo treatment. The Lp(a) levels were measured in plasma samples obtained prior to randomization in 233 cases (participants who developed CHD in the course of the study) and 390 matched CHD-free controls. A total of 96.95% of the subjects were white, 2.25% were black, and 0.80% were of other race. MAIN OUTCOME MEASURE: Coronary heart disease (either fatal or nonfatal) events during a follow-up of 7 to 10 years. RESULTS: The Lp(a) levels were significantly higher (21%) in cases than in controls (23.7 mg/dL [0.59 mmol/L] and 19.5 mg/dL [0.49 mmol/L], respectively; P < .02). This difference was still statistically significant (P < .01) after controlling for age, body mass index, cigarette smoking, blood pressure, low-density lipoprotein cholesterol level, and high-density lipoprotein cholesterol level. When subjects were divided by treatment, both cholestyramine-treated and placebo-treated CHD subjects had Lp(a) levels 20% to 22% greater than their matched controls. However, possibly because of smaller sample sizes, these differences were no longer statistically significant. CONCLUSIONS: Our data are consistent with the concept that an elevated Lp(a) level is an independent risk factor for CHD in hypercholesterolemic white men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [223]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,895
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
The mysteries of lipoprotein(a).
Utermann, G. (1989) · Science · doi:10.1126/science.2530631 · Cited by 1,257
Boerwinkle, E., Leffert, C. C., Lin, J., Lackner, C., Chiesa, G., & Hobbs, H. H. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115855 · Cited by 973
Dahlén, G., Guyton, J. R., Attar, M., Farmer, J. A., Kautz, J. A., & Gotto, A. M. (1986) · Circulation · doi:10.1161/01.cir.74.4.758 · Cited by 910
Hajjar, K. A., Gavishi, D., Breslow, J. L., & Nachman, R. L. (1989) · Nature · doi:10.1038/339303a0 · Cited by 699
Familial lipoprotein disorders in patients with premature coronary artery disease.
Genest, J. J., Martin-Munley, S., McNamara, J. R., Ordovás, J. M., Jenner, J. L., Myers, R. H., Silberman, S. R., Wilson, P. W., Salem, D. N., & Schaefer, E. J. (1992) · Circulation · doi:10.1161/01.cir.85.6.2025 · Cited by 598
Self-citationSeed, M., Hoppichler, F., Reaveley, D. A., McCarthy, S., Thompson, G. R., Boerwinkle, E., & Utermann, G. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005243222104 · Cited by 584
Cited by
Sorted by citations
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Lipoprotein(a) and Coronary Heart Disease
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Mahoney, L., Burns, T., Stanford, W., Thompson, B., Witt, J., Rost, C. A., & Lauer, R. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00461-0 · Cited by 693
Metadata
- Authors
- Schaefer, E. J.
- Affiliations
- Tufts University (US)
- Corresponding author
- Schaefer, Ernst J.
- ORCID
- Schaefer, Ernst J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1994-04-06
- Volume
- 271
- Issue
- 13
- Pages
- 999
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2085959182
- Cited by
- 487
- References
- 41
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 7 · 2022: 2 · 2021: 4 · 2020: 6 · 2019: 2 · 2018: 4 · 2017: 10 · 2016: 9 · 2015: 10 · 2014: 3 · 2013: 5 · 2012: 10
- FWCI
- 57.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HV83-03)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), coronary artery disease, cardiovascular risk factors, hypercholesterolemia, cholestyramine, men, LDL cholesterol, primary prevention
- MeSH terms
- Adult, Aged, Cholestyramine Resin, Coronary Disease, Humans, Hypercholesterolemia, Lipids, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Risk Factors, Logistic Models, Case-Control Studies, Lipoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
